88192-99-8
Chemical Structure
Myxopyronin B
- CAS No.: 88192-99-8
- Formula:C24H33NO6
- Molecular Weight:431.52
InChIKey: SPQDIDVJAZFBRL-WXFBSNOUSA-N
SMILES: CCCC/C(C)=C/C=C(C)/C(C1=C(C=C(OC1=O)[C@H](C)CC/C=C/NC(OC)=O)O)=O
Biological Activity: Myxopyronin B is an α-pyrone natural product derived from Myxococcus fulvus and acts as an inhibitor of the switch region of bacterial RNA polymerase (RNAP) (IC50 = 24 μM). Myxopyronin B binds to the switch region of RNA polymerase, locking the polymerase clamp into a closed conformation and thereby inhibiting transcription initiation. Myxopyronin B exhibits antibacterial activity against Staphylococcus aureus and Clostridioides difficile, inhibits the early synthesis of toxins A and B, and reduces the abundance of proteins in the branched-chain amino acid fermentation pathway. Myxopyronin B is useful for research related to bacterial infections[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Myxopyronin B | Myxopyronin B is an α-pyrone natural product derived from Myxococcus fulvus and acts as an inhibitor of the switch region of bacterial RNA polymerase (RNAP) (IC50 = 24 μM). Myxopyronin B binds to the switch region of RNA polymerase, locking the polymerase clamp into a closed conformation and thereby inhibiting transcription initiation. Myxopyronin B exhibits antibacterial activity against Staphylococcus aureus and Clostridioides difficile, inhibits the early synthesis of toxins A and B, and reduces the abundance of proteins in the branched-chain amino acid fermentation pathway. Myxopyronin B is useful for research related to bacterial infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Moy TI, et al. Evaluating the activity of the RNA polymerase inhibitor myxopyronin B against Staphylococcus aureus. FEMS microbiology letters. 2011 Jun;319(2):176-9.
- [2]. Brauer M, et al. Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis. Gut pathogens. 2022 Jan 06;14(1):4.
